Healthcare Business

462542665

Just How Expensive Is the Pharmacyclics Buyout?

Pharmacyclics Inc. (NASDAQ: PCYC) has seen its stock surge in the past week as rumors swirl about a potential acquisition. News finally broke late Wednesday that there was an official ...
Read Full Story »
Biotechnology word cloud

Novogen Makes Big Step In Fighting Brain Cancer

Novogen Limited (NASDAQ: NVGN) confirmed Wednesday morning that one of its lead candidate products, TRXE-009, has shown potential to become an important new therapy for both adult and pediatric brain ...
Read Full Story »
biotech

The 5 Most Loved Biotech Stocks of Portfolio Managers

With the market continuing to grind higher, and the memories of the first time the Nasdaq hit 5,000 getting a fair amount of airplay and commentary, the question for most ...
Read Full Story »
biotech

Oncolytics Newest Orphan Drug Designation

Oncolytics Biotech Inc. (NASDAQ: ONCY) announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation for Reolysin. Reolysin is the company’s lead product candidate that is designated ...
Read Full Story »
health care

Key Analyst Weighs In on Boston Scientific Acquisition

Boston Scientific Corp. (NYSE: BSX) announced that it entered into a definitive agreement with Endo International PLC (NASDAQ: ENDP) to acquire its American Medical Systems urology portfolio. The deal calls for ...
Read Full Story »
Pills

Is the Actavis $21 Billion Bond Sale Just the First?

Generally speaking, when one company offers to buy another for $66 billion, the acquiring company has to borrow money in order to pay up. That is what Actavis PLC (NYSE: ...
Read Full Story »
Comfortable hospital bed

4 High-Yield Health Care Real Estate Investment Trusts to Buy Now

If there was ever an awesome and timely combination in a growth and income investment, it is the health care real estate investment trust (REIT). They combine the health care ...
Read Full Story »
Biotechnology word cloud

4 Biotechs Expected to See Huge Buying on PowerShares Rebalance

All the major money management firms that run exchange traded funds have to do regular quarterly rebalances to reset their portfolios to the proper allocation levels. When they do rebalance ...
Read Full Story »
biotech

Are Mylan Earnings Enough?

Monday after the markets closed, Mylan, Inc. (NASDAQ: MYL) reported its fourth-quarter financial results as in line with estimates. Specifically the company had $1.05 in earnings per share (EPS) and ...
Read Full Story »
road fork sign

Has Biocept Reached an Inflection Point?

Biocept Inc. (NASDAQ: BIOC) has seen its stock move up over 200% in the past week, only to give back about 20% in Thursday's trading. This initial jump was brought about when Biocept ...
Read Full Story »
health care

5 Health Care Stocks That Are Possible Buyout Candidates

One great way for companies to expand growth, earnings and product offerings beyond internal organic expansion is to go the takeover route. While sometimes it can prove to be dilutive, ...
Read Full Story »
research

Short Sellers Increase Bets Against Biotech as Shares Continue to Rise

The short interest data are out for the February 13 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Comfortable hospital bed

Top UBS Health Care Stocks to Buy for 2015 and Beyond

As the market surges higher, investors start to get a touch more concerned about where they allocate capital. One sector that is consistently ranked as an overweight from almost every ...
Read Full Story »
135093244

Steep Discount on Health Care REIT Secondary Offering

Health Care REIT Inc. (NYSE: HCN) has priced its underwritten public secondary offering of 17 million shares of its common stock at a price of $75.50 per share. While it ...
Read Full Story »
pills

Is Express Scripts 2015 Guidance Good Enough For All-Time Highs?

After the markets closed Monday, Express Scripts Holding Company (NASDAQ: ESRX) reported its fourth-quarter financial results as $1.39 in earnings per share (EPS) and $26.31 billion in revenue. This is ...
Read Full Story »